

DOCKET NO.: A0848.70007US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Beirnaert et al.
Serial No.: 10/534,345
Confirmation No.: 4825
Filed: May 9, 2005
For: SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST
INTERFERON-GAMMA AND USES THEREFOR
Examiner: Zachary S. Skelding
Art Unit: 1644

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following are remarks concerning the other information cited:

An English language Abstract is provided for Japanese Publication No. JP 62175426 A (Cite No. B19 on Form PTO-1449).

PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Serial No.: 10/534,345
Conf. No.: 4825

- 3 -

Art Unit: 1644

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:


John R. Van Amsterdam, Ph.D.
Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: A0848.70007US00

Date: June 11, 2007

xNDDx

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/534,345	ATTY. DOCKET NO.: A0848.70007US00		
				FILING DATE: May 9, 2005	CONFIRMATION NO.: 4825		
				APPLICANT: Silence et al.			
				GROUP ART UNIT: 1644		EXAMINER: Skelding, Zachary S.	
Sheet	1	of	1				

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A8	2002/0165387	A1	Kerr Anderson et al.	11-07-2002
	A9	2002/0001587	A1	Erickson et al.	01-03-2002

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B19	JP	62175426	A	Shimizu Kazufumi	08-01-1987	Abstract

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C15	WORLEDGE K.L. et al., "Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats," <i>Digestive Diseases and Sciences</i> December 2000; 45(12): 2298-2305	
	C16	TEITELBAUM R. et al., "A mAB recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival," <i>Proc.. Natl. Acad. Sci. USA</i> December 1998; 95(26): 15688-15693	
	C17	SKURKOVICH S. et al., "Treatment of corneal transplant rejection in humans with anti-interferon-gamma antibodies," <i>American Journal of Ophthalmology</i> June 2002; 133(6): 829-830	
	C18	SHIMAMOTO C. et al., "Inhibition of Helicobacter pylori infection by orally administered yolk-derived anti-Helicobacter pylori antibody," Database Biosis Biosciences Information Service, Philadelphia, PA, US; May 2002	Abstract

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]